 |
市場調查報告書
商品編碼
1412579
人類免疫力缺乏病毒治療市場：按藥物類別、最終用戶、配銷通路- 全球預測 2024-2030Human Immunodeficiency Virus Therapeutics Market by Drug Class (Coreceptor Antagonists, Entry & Fusion Inhibitors, Integrase Inhibitors), End-User (Hospitals & Clinics, Specialty Centers), Distribution Channel - Global Forecast 2024-2030 |
||||||
價格
※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。
人類免疫力缺乏病毒治療市場規模預計2023年為193.4億美元，2024年達202.8億美元，預計2030年將達265.5億美元，複合年成長率為4.63%。
人類免疫力缺乏病毒治療的全球市場
| 主要市場統計 | |
|---|---|
| 基準年[2023] | 193.4億美元 |
| 預測年份 [2024] | 202.8億美元 |
| 預測年份 [2030] | 265.5億美元 |
| 複合年成長率（%） | 4.63% |
FPNV定位矩陣
FPNV 定位矩陣對於評估人類免疫力缺乏病毒治療市場至關重要。我們檢視與業務策略和產品滿意度相關的關鍵指標，以對供應商進行全面評估。這種深入的分析使用戶能夠根據自己的要求做出資訊的決策。根據評估，供應商被分為四個成功程度不同的像限：前沿（F）、探路者（P）、利基（N）和重要（V）。
市場佔有率分析
市場佔有率分析是一種綜合工具，可以對人類免疫力缺乏病毒治療市場供應商的現狀進行深入而深入的研究。全面比較和分析供應商在整體收益、基本客群和其他關鍵指標方面的貢獻，以便更好地了解公司的績效及其在爭奪市場佔有率時面臨的挑戰。此外，該分析還提供了對該行業競爭特徵的寶貴考察，包括在研究基準年觀察到的累積、分散主導地位和合併特徵等因素。這種詳細程度的提高使供應商能夠做出更資訊的決策並制定有效的策略，從而在市場上獲得競爭優勢。
該報告對以下幾個方面提供了寶貴的見解：
1-市場滲透率：提供有關主要企業所服務的市場的全面資訊。
2-市場開拓：我們深入研究利潤豐厚的新興市場，並分析它們在成熟細分市場中的滲透率。
3- 市場多元化：提供有關新產品發布、開拓地區、最新發展和投資的詳細資訊。
4-競爭力評估與資訊：對主要企業的市場佔有率、策略、產品、認證、監管狀況、專利狀況、製造能力等進行全面評估。
5- 產品開發與創新：提供對未來技術、研發活動和突破性產品開發的見解。
本報告解決了以下關鍵問題：
1-人類免疫力缺乏病毒治療市場的市場規模和預測是多少？
2-在人類免疫力缺乏病毒治療市場的預測期內，有哪些產品、細分市場、應用和領域需要考慮投資？
3-人類免疫力缺乏病毒治療市場的技術趨勢和法律規範是什麼？
4-人類免疫力缺乏病毒治療市場主要供應商的市場佔有率是多少？
5-進入人類免疫力缺乏病毒治療市場的適當型態和策略手段是什麼？
目錄
第1章 前言
第2章調查方法
第3章執行摘要
第4章市場概況
第5章市場洞察
- 市場動態
- 促進因素
- 愛滋病毒感染疾病正在增加，特別是在年輕人中
- 提高對感染疾病和有效治療方法的認知
- 增加資金和藥物核准
- 抑制因素
- 抗逆轉錄病毒治療成本高且抗藥性增加
- 機會
- 政府與各非政府組織合作的努力
- HIV 即時檢測的技術進步
- 任務
- 對感染途徑缺乏認知
- 促進因素
- 市場區隔分析
- 市場趨勢分析
- 高通膨的累積效應
- 波特五力分析
- 價值鍊和關鍵路徑分析
- 法律規範
第6章依藥物類別分類的人類免疫力缺乏病毒治療藥物市場
- 共受體拮抗劑
- 進入和融合抑制劑
- 整合酶抑制劑
- 非核苷類逆轉錄酶抑制劑
- 核苷類似物逆轉錄酶抑制劑
- 蛋白酶抑制劑
第7章人類免疫力缺乏病毒治療市場：依最終用戶分類
- 醫院和診所
- 專業中心
第8章人類免疫力缺乏病毒治療藥物市場：按配銷通路
- 醫院藥房
- 網路藥房
- 零售藥房
第9章北美和南美人類免疫力缺乏病毒治療藥物市場
- 阿根廷
- 巴西
- 加拿大
- 墨西哥
- 美國
第10章亞太地區人類免疫力缺乏病毒治療市場
- 澳洲
- 中國
- 印度
- 印尼
- 日本
- 馬來西亞
- 菲律賓
- 新加坡
- 韓國
- 台灣
- 泰國
- 越南
第11章歐洲、中東和非洲人類免疫力缺乏病毒治療藥物市場
- 丹麥
- 埃及
- 芬蘭
- 法國
- 德國
- 以色列
- 義大利
- 荷蘭
- 奈及利亞
- 挪威
- 波蘭
- 卡達
- 俄羅斯
- 沙烏地阿拉伯
- 南非
- 西班牙
- 瑞典
- 瑞士
- 土耳其
- 阿拉伯聯合大公國
- 英國
第12章競爭形勢
- FPNV定位矩陣
- 市場佔有率分析：按主要企業分類
- 主要企業競爭情境分析
第13章競爭產品組合
- 主要公司簡介
- AbbVie, Inc.
- BioNTech SE
- Boehringer Ingelheim GmbH
- Bristol-Myers Squibb Company
- Cipla Limited
- CytoDyn Inc.
- Dewpoint Therapeutics Inc.
- F. Hoffmann-La Roche Ltd.
- Genentech, Inc.
- Gilead Sciences, Inc.
- GlaxoSmithKline PLC
- ImmunityBio, Inc.
- Johnson & Johnson Services, Inc.
- Mylan NV
- Pfizer, Inc.
- Starpharma Holdings Limited
- TaiMed Biologics, Inc.
- Teva Pharmaceutical Industries Ltd.
- 主要產品系列
第14章附錄
- 討論指南
- 關於許可證和定價
Product Code: MRR-ED54C46E8D0A
[194 Pages Report] The Human Immunodeficiency Virus Therapeutics Market size was estimated at USD 19.34 billion in 2023 and expected to reach USD 20.28 billion in 2024, at a CAGR 4.63% to reach USD 26.55 billion by 2030.
Global Human Immunodeficiency Virus Therapeutics Market
| KEY MARKET STATISTICS | |
|---|---|
| Base Year [2023] | USD 19.34 billion |
| Estimated Year [2024] | USD 20.28 billion |
| Forecast Year [2030] | USD 26.55 billion |
| CAGR (%) | 4.63% |
FPNV Positioning Matrix
The FPNV Positioning Matrix is pivotal in evaluating the Human Immunodeficiency Virus Therapeutics Market. It offers a comprehensive assessment of vendors, examining key metrics related to Business Strategy and Product Satisfaction. This in-depth analysis empowers users to make well-informed decisions aligned with their requirements. Based on the evaluation, the vendors are then categorized into four distinct quadrants representing varying levels of success: Forefront (F), Pathfinder (P), Niche (N), or Vital (V).
Market Share Analysis
The Market Share Analysis is a comprehensive tool that provides an insightful and in-depth examination of the current state of vendors in the Human Immunodeficiency Virus Therapeutics Market. By meticulously comparing and analyzing vendor contributions in terms of overall revenue, customer base, and other key metrics, we can offer companies a greater understanding of their performance and the challenges they face when competing for market share. Additionally, this analysis provides valuable insights into the competitive nature of the sector, including factors such as accumulation, fragmentation dominance, and amalgamation traits observed over the base year period studied. With this expanded level of detail, vendors can make more informed decisions and devise effective strategies to gain a competitive edge in the market.
Key Company Profiles
The report delves into recent significant developments in the Human Immunodeficiency Virus Therapeutics Market, highlighting leading vendors and their innovative profiles. These include AbbVie, Inc., BioNTech SE, Boehringer Ingelheim GmbH, Bristol-Myers Squibb Company, Cipla Limited, CytoDyn Inc., Dewpoint Therapeutics Inc., F. Hoffmann-La Roche Ltd., Genentech, Inc., Gilead Sciences, Inc., GlaxoSmithKline PLC, ImmunityBio, Inc., Johnson & Johnson Services, Inc., Mylan NV, Pfizer, Inc., Starpharma Holdings Limited, TaiMed Biologics, Inc., and Teva Pharmaceutical Industries Ltd..
Market Segmentation & Coverage
This research report categorizes the Human Immunodeficiency Virus Therapeutics Market to forecast the revenues and analyze trends in each of the following sub-markets:
- Drug Class
- Coreceptor Antagonists
- Entry & Fusion Inhibitors
- Integrase Inhibitors
- Non-Nucleoside Reverse Transcriptase Inhibitors
- Nucleoside-Analog Reverse Transcriptase Inhibitors
- Protease Inhibitors
- End-User
- Hospitals & Clinics
- Specialty Centers
- Distribution Channel
- Hospital Pharmacies
- Online Pharmacies
- Retail Pharmacies
- Region
- Americas
- Argentina
- Brazil
- Canada
- Mexico
- United States
- California
- Florida
- Illinois
- New York
- Ohio
- Pennsylvania
- Texas
- Asia-Pacific
- Australia
- China
- India
- Indonesia
- Japan
- Malaysia
- Philippines
- Singapore
- South Korea
- Taiwan
- Thailand
- Vietnam
- Europe, Middle East & Africa
- Denmark
- Egypt
- Finland
- France
- Germany
- Israel
- Italy
- Netherlands
- Nigeria
- Norway
- Poland
- Qatar
- Russia
- Saudi Arabia
- South Africa
- Spain
- Sweden
- Switzerland
- Turkey
- United Arab Emirates
- United Kingdom
- Americas
The report offers valuable insights on the following aspects:
1. Market Penetration: It presents comprehensive information on the market provided by key players.
2. Market Development: It delves deep into lucrative emerging markets and analyzes the penetration across mature market segments.
3. Market Diversification: It provides detailed information on new product launches, untapped geographic regions, recent developments, and investments.
4. Competitive Assessment & Intelligence: It conducts an exhaustive assessment of market shares, strategies, products, certifications, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players.
5. Product Development & Innovation: It offers intelligent insights on future technologies, R&D activities, and breakthrough product developments.
The report addresses key questions such as:
1. What is the market size and forecast of the Human Immunodeficiency Virus Therapeutics Market?
2. Which products, segments, applications, and areas should one consider investing in over the forecast period in the Human Immunodeficiency Virus Therapeutics Market?
3. What are the technology trends and regulatory frameworks in the Human Immunodeficiency Virus Therapeutics Market?
4. What is the market share of the leading vendors in the Human Immunodeficiency Virus Therapeutics Market?
5. Which modes and strategic moves are suitable for entering the Human Immunodeficiency Virus Therapeutics Market?
Table of Contents
1. Preface
- 1.1. Objectives of the Study
- 1.2. Market Segmentation & Coverage
- 1.3. Years Considered for the Study
- 1.4. Currency & Pricing
- 1.5. Language
- 1.6. Limitations
- 1.7. Assumptions
- 1.8. Stakeholders
2. Research Methodology
- 2.1. Define: Research Objective
- 2.2. Determine: Research Design
- 2.3. Prepare: Research Instrument
- 2.4. Collect: Data Source
- 2.5. Analyze: Data Interpretation
- 2.6. Formulate: Data Verification
- 2.7. Publish: Research Report
- 2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
- 4.1. Introduction
- 4.2. Human Immunodeficiency Virus Therapeutics Market, by Region
5. Market Insights
- 5.1. Market Dynamics
- 5.1.1. Drivers
- 5.1.1.1. Growing prevalence of HIV infections particularly amongst the youth
- 5.1.1.2. Rising awareness about infection and availability of efficient treatments
- 5.1.1.3. Increasing funding and approval of drugs
- 5.1.2. Restraints
- 5.1.2.1. High cost of antiretroviral therapies and rising drug resistance
- 5.1.3. Opportunities
- 5.1.3.1. Collaborative efforts of government and various NGOs
- 5.1.3.2. Technological advancements in point-of-care testing for HIV
- 5.1.4. Challenges
- 5.1.4.1. Lack of awareness about the mode of transmission
- 5.1.1. Drivers
- 5.2. Market Segmentation Analysis
- 5.3. Market Trend Analysis
- 5.4. Cumulative Impact of High Inflation
- 5.5. Porter's Five Forces Analysis
- 5.5.1. Threat of New Entrants
- 5.5.2. Threat of Substitutes
- 5.5.3. Bargaining Power of Customers
- 5.5.4. Bargaining Power of Suppliers
- 5.5.5. Industry Rivalry
- 5.6. Value Chain & Critical Path Analysis
- 5.7. Regulatory Framework
6. Human Immunodeficiency Virus Therapeutics Market, by Drug Class
- 6.1. Introduction
- 6.2. Coreceptor Antagonists
- 6.3. Entry & Fusion Inhibitors
- 6.4. Integrase Inhibitors
- 6.5. Non-Nucleoside Reverse Transcriptase Inhibitors
- 6.6. Nucleoside-Analog Reverse Transcriptase Inhibitors
- 6.7. Protease Inhibitors
7. Human Immunodeficiency Virus Therapeutics Market, by End-User
- 7.1. Introduction
- 7.2. Hospitals & Clinics
- 7.3. Specialty Centers
8. Human Immunodeficiency Virus Therapeutics Market, by Distribution Channel
- 8.1. Introduction
- 8.2. Hospital Pharmacies
- 8.3. Online Pharmacies
- 8.4. Retail Pharmacies
9. Americas Human Immunodeficiency Virus Therapeutics Market
- 9.1. Introduction
- 9.2. Argentina
- 9.3. Brazil
- 9.4. Canada
- 9.5. Mexico
- 9.6. United States
10. Asia-Pacific Human Immunodeficiency Virus Therapeutics Market
- 10.1. Introduction
- 10.2. Australia
- 10.3. China
- 10.4. India
- 10.5. Indonesia
- 10.6. Japan
- 10.7. Malaysia
- 10.8. Philippines
- 10.9. Singapore
- 10.10. South Korea
- 10.11. Taiwan
- 10.12. Thailand
- 10.13. Vietnam
11. Europe, Middle East & Africa Human Immunodeficiency Virus Therapeutics Market
- 11.1. Introduction
- 11.2. Denmark
- 11.3. Egypt
- 11.4. Finland
- 11.5. France
- 11.6. Germany
- 11.7. Israel
- 11.8. Italy
- 11.9. Netherlands
- 11.10. Nigeria
- 11.11. Norway
- 11.12. Poland
- 11.13. Qatar
- 11.14. Russia
- 11.15. Saudi Arabia
- 11.16. South Africa
- 11.17. Spain
- 11.18. Sweden
- 11.19. Switzerland
- 11.20. Turkey
- 11.21. United Arab Emirates
- 11.22. United Kingdom
12. Competitive Landscape
- 12.1. FPNV Positioning Matrix
- 12.2. Market Share Analysis, By Key Player
- 12.3. Competitive Scenario Analysis, By Key Player
13. Competitive Portfolio
- 13.1. Key Company Profiles
- 13.1.1. AbbVie, Inc.
- 13.1.2. BioNTech SE
- 13.1.3. Boehringer Ingelheim GmbH
- 13.1.4. Bristol-Myers Squibb Company
- 13.1.5. Cipla Limited
- 13.1.6. CytoDyn Inc.
- 13.1.7. Dewpoint Therapeutics Inc.
- 13.1.8. F. Hoffmann-La Roche Ltd.
- 13.1.9. Genentech, Inc.
- 13.1.10. Gilead Sciences, Inc.
- 13.1.11. GlaxoSmithKline PLC
- 13.1.12. ImmunityBio, Inc.
- 13.1.13. Johnson & Johnson Services, Inc.
- 13.1.14. Mylan NV
- 13.1.15. Pfizer, Inc.
- 13.1.16. Starpharma Holdings Limited
- 13.1.17. TaiMed Biologics, Inc.
- 13.1.18. Teva Pharmaceutical Industries Ltd.
- 13.2. Key Product Portfolio
14. Appendix
- 14.1. Discussion Guide
- 14.2. License & Pricing
LIST OF FIGURES
- FIGURE 1. HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET RESEARCH PROCESS
- FIGURE 2. HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, 2023 VS 2030
- FIGURE 3. HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, 2018-2030 (USD MILLION)
- FIGURE 4. HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY REGION, 2023 VS 2030 (%)
- FIGURE 5. HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
- FIGURE 6. HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET DYNAMICS
- FIGURE 7. HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2023 VS 2030 (%)
- FIGURE 8. HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2023 VS 2024 VS 2030 (USD MILLION)
- FIGURE 9. HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY END-USER, 2023 VS 2030 (%)
- FIGURE 10. HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY END-USER, 2023 VS 2024 VS 2030 (USD MILLION)
- FIGURE 11. HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2023 VS 2030 (%)
- FIGURE 12. HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2023 VS 2024 VS 2030 (USD MILLION)
- FIGURE 13. AMERICAS HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
- FIGURE 14. AMERICAS HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
- FIGURE 15. UNITED STATES HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY STATE, 2023 VS 2030 (%)
- FIGURE 16. UNITED STATES HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
- FIGURE 17. ASIA-PACIFIC HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
- FIGURE 18. ASIA-PACIFIC HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
- FIGURE 19. EUROPE, MIDDLE EAST & AFRICA HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
- FIGURE 20. EUROPE, MIDDLE EAST & AFRICA HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
- FIGURE 21. HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET, FPNV POSITIONING MATRIX, 2023
- FIGURE 22. HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SHARE, BY KEY PLAYER, 2023
LIST OF TABLES
- TABLE 1. HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SEGMENTATION & COVERAGE
- TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
- TABLE 3. HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, 2018-2030 (USD MILLION)
- TABLE 4. GLOBAL HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
- TABLE 5. HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
- TABLE 6. HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY CORECEPTOR ANTAGONISTS, BY REGION, 2018-2030 (USD MILLION)
- TABLE 7. HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY ENTRY & FUSION INHIBITORS, BY REGION, 2018-2030 (USD MILLION)
- TABLE 8. HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY INTEGRASE INHIBITORS, BY REGION, 2018-2030 (USD MILLION)
- TABLE 9. HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS, BY REGION, 2018-2030 (USD MILLION)
- TABLE 10. HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY NUCLEOSIDE-ANALOG REVERSE TRANSCRIPTASE INHIBITORS, BY REGION, 2018-2030 (USD MILLION)
- TABLE 11. HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY PROTEASE INHIBITORS, BY REGION, 2018-2030 (USD MILLION)
- TABLE 12. HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
- TABLE 13. HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY HOSPITALS & CLINICS, BY REGION, 2018-2030 (USD MILLION)
- TABLE 14. HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY SPECIALTY CENTERS, BY REGION, 2018-2030 (USD MILLION)
- TABLE 15. HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
- TABLE 16. HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
- TABLE 17. HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
- TABLE 18. HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
- TABLE 19. AMERICAS HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
- TABLE 20. AMERICAS HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
- TABLE 21. AMERICAS HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
- TABLE 22. AMERICAS HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
- TABLE 23. ARGENTINA HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
- TABLE 24. ARGENTINA HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
- TABLE 25. ARGENTINA HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
- TABLE 26. BRAZIL HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
- TABLE 27. BRAZIL HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
- TABLE 28. BRAZIL HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
- TABLE 29. CANADA HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
- TABLE 30. CANADA HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
- TABLE 31. CANADA HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
- TABLE 32. MEXICO HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
- TABLE 33. MEXICO HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
- TABLE 34. MEXICO HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
- TABLE 35. UNITED STATES HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
- TABLE 36. UNITED STATES HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
- TABLE 37. UNITED STATES HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
- TABLE 38. UNITED STATES HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
- TABLE 39. ASIA-PACIFIC HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
- TABLE 40. ASIA-PACIFIC HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
- TABLE 41. ASIA-PACIFIC HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
- TABLE 42. ASIA-PACIFIC HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
- TABLE 43. AUSTRALIA HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
- TABLE 44. AUSTRALIA HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
- TABLE 45. AUSTRALIA HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
- TABLE 46. CHINA HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
- TABLE 47. CHINA HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
- TABLE 48. CHINA HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
- TABLE 49. INDIA HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
- TABLE 50. INDIA HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
- TABLE 51. INDIA HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
- TABLE 52. INDONESIA HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
- TABLE 53. INDONESIA HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
- TABLE 54. INDONESIA HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
- TABLE 55. JAPAN HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
- TABLE 56. JAPAN HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
- TABLE 57. JAPAN HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
- TABLE 58. MALAYSIA HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
- TABLE 59. MALAYSIA HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
- TABLE 60. MALAYSIA HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
- TABLE 61. PHILIPPINES HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
- TABLE 62. PHILIPPINES HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
- TABLE 63. PHILIPPINES HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
- TABLE 64. SINGAPORE HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
- TABLE 65. SINGAPORE HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
- TABLE 66. SINGAPORE HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
- TABLE 67. SOUTH KOREA HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
- TABLE 68. SOUTH KOREA HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
- TABLE 69. SOUTH KOREA HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
- TABLE 70. TAIWAN HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
- TABLE 71. TAIWAN HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
- TABLE 72. TAIWAN HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
- TABLE 73. THAILAND HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
- TABLE 74. THAILAND HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
- TABLE 75. THAILAND HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
- TABLE 76. VIETNAM HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
- TABLE 77. VIETNAM HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
- TABLE 78. VIETNAM HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
- TABLE 79. EUROPE, MIDDLE EAST & AFRICA HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
- TABLE 80. EUROPE, MIDDLE EAST & AFRICA HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
- TABLE 81. EUROPE, MIDDLE EAST & AFRICA HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
- TABLE 82. EUROPE, MIDDLE EAST & AFRICA HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
- TABLE 83. DENMARK HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
- TABLE 84. DENMARK HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
- TABLE 85. DENMARK HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
- TABLE 86. EGYPT HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
- TABLE 87. EGYPT HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
- TABLE 88. EGYPT HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
- TABLE 89. FINLAND HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
- TABLE 90. FINLAND HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
- TABLE 91. FINLAND HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
- TABLE 92. FRANCE HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
- TABLE 93. FRANCE HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
- TABLE 94. FRANCE HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
- TABLE 95. GERMANY HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
- TABLE 96. GERMANY HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
- TABLE 97. GERMANY HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
- TABLE 98. ISRAEL HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
- TABLE 99. ISRAEL HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
- TABLE 100. ISRAEL HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
- TABLE 101. ITALY HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
- TABLE 102. ITALY HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
- TABLE 103. ITALY HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
- TABLE 104. NETHERLANDS HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
- TABLE 105. NETHERLANDS HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
- TABLE 106. NETHERLANDS HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
- TABLE 107. NIGERIA HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
- TABLE 108. NIGERIA HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
- TABLE 109. NIGERIA HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
- TABLE 110. NORWAY HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
- TABLE 111. NORWAY HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
- TABLE 112. NORWAY HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
- TABLE 113. POLAND HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
- TABLE 114. POLAND HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
- TABLE 115. POLAND HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
- TABLE 116. QATAR HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
- TABLE 117. QATAR HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
- TABLE 118. QATAR HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
- TABLE 119. RUSSIA HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
- TABLE 120. RUSSIA HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
- TABLE 121. RUSSIA HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
- TABLE 122. SAUDI ARABIA HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
- TABLE 123. SAUDI ARABIA HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
- TABLE 124. SAUDI ARABIA HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
- TABLE 125. SOUTH AFRICA HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
- TABLE 126. SOUTH AFRICA HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
- TABLE 127. SOUTH AFRICA HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
- TABLE 128. SPAIN HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
- TABLE 129. SPAIN HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
- TABLE 130. SPAIN HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
- TABLE 131. SWEDEN HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
- TABLE 132. SWEDEN HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
- TABLE 133. SWEDEN HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
- TABLE 134. SWITZERLAND HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
- TABLE 135. SWITZERLAND HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
- TABLE 136. SWITZERLAND HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
- TABLE 137. TURKEY HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
- TABLE 138. TURKEY HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
- TABLE 139. TURKEY HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
- TABLE 140. UNITED ARAB EMIRATES HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
- TABLE 141. UNITED ARAB EMIRATES HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
- TABLE 142. UNITED ARAB EMIRATES HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
- TABLE 143. UNITED KINGDOM HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
- TABLE 144. UNITED KINGDOM HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
- TABLE 145. UNITED KINGDOM HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
- TABLE 146. HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET, FPNV POSITIONING MATRIX, 2023
- TABLE 147. HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET SHARE, BY KEY PLAYER, 2023
- TABLE 148. HUMAN IMMUNODEFICIENCY VIRUS THERAPEUTICS MARKET LICENSE & PRICING
02-2729-4219
+886-2-2729-4219
HIV 診斷市場：按模式、測試類型和最終用途：2023-2032 年全球機會分析和產業預測
HIV 診斷與治療：全球市場
HIV 相關脂肪營養不良市場 - 2018-2028 年全球產業規模、佔有率、趨勢、機會和預測，按類型、給藥途徑、配銷通路、地區和競爭細分
人類免疫力缺乏病毒治療藥物市場規模、佔有率、趨勢分析報告：按藥物類型、藥物類別、地區和細分市場預測，2023-2030 年
全球 HIV 診斷市場，到 2030 年的預測：按產品、測試類型、最終用戶和地區進行的全球分析
全球口服抗病毒藥物市場：按適應症（肝炎、人類免疫缺陷病毒、流感等）、藥物類別、分銷渠道劃分：機會分析和行業預測，2021-2031 年
人免疫力缺乏病毒(HIV)治療藥的全球市場:佔有率，規模，趨勢，產業分析報告，各流通管道(醫院藥局，零售藥局，線上藥局，其他)，各醫藥品分類，各地區，各市場區隔預測(2022年～2030年)